---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-025827"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:21:36.777189+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical FY2024 revenue down $91K; clinical trial enrollment advances

## Summary
- Net revenues decreased $91K YoY; cash and equivalents were $5.5M as of Dec 31, 2024.
- R&D expenses increased $1.2M driven by headcount for Acclaim cochlear implant pivotal study.
- FDA approved pivotal trial; 6 of 10 planned first-stage participants enrolled and implanted.
- New CPT codes for fully implanted middle ear implants effective July 2025; Hearing Device Coverage Clarification Act reintroduced.
- G&A expenses down $438K reflecting lower professional fees post-business combination.

## SEC filing metadata
- accession: 0001213900-25-025827
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390025025827/0001213900-25-025827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390025025827/ea0236135-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-025827
- JSON: https://secwatch.observer/filing/0001213900-25-025827.json
- Plain text: https://secwatch.observer/filing/0001213900-25-025827.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.